AXL and melanoma: Resistance to BRAF inhibition (BRAFi) is a significant clinical obstacle, as certain melanoma cells can downregulate key regulators of melanocyte differentiation, such as MITF, and upregulate RTKs like AXL and EGFR [14, 15].